StockNews.AI
NVAX
StockNews.AI
180 days

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

1. NVAX to report Q4 and full year 2024 financial results. Earnings details may influence investor outlook. 2. Conference call set for February 27, 2025, at 8:30 a.m. ET. Stakeholders can join via provided webcast. 3. Replay and dial-in options available until early March 2025. Full operational highlights and Q4 data expected. 4. Event details published on NVAX website for investors and media. Preparation for earnings discussion is underway.

3m saved
Insight
Article

FAQ

Why Neutral?

The announcement sets the stage for earnings-induced volatility, yet outcome remains uncertain. Similar pre-earnings events have historically had mixed short-term impact on biotech stocks.

How important is it?

Scheduled earnings reports are key for assessing NVAX's current performance. The release timing and detailed operational highlights warrant investor attention, though outcome surprises remain possible.

Why Short Term?

Earnings reports typically trigger immediate market reactions with temporary volatility. Long-term dynamics depend on product pipeline and sector trends.

Related Companies

MRNABNTX
GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows: Conference call details: Date: February 27, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3PsP11e Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Replay details: Date: Available starting at 11:30 a.m. U.S. ET, February 27, 2025, until 11:59 p.m. U.S. ET, March 6, 2025 Dial-in number: (888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International) Passcode: 79349# Webcast: ir.novavax.com/events, until March 29, 2025 About NovavaxNovavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts: InvestorsLuis Sanay, CFA240-268-2022[email protected] MediaGiovanna Chandler202-709-5563[email protected] SOURCE Novavax, Inc.

Related News